Bio-Rad Laboratories, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Norman D. Schwartz
- Full Time Employees
- 7,700
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1000 Alfred Nobel Drive Hercules CA United States of America 94547
- IPO Date
- Feb 27, 1980
- CIK
- 0000012208
- Website
- bio-rad.com
- Similar Companies
- Business
- Bio-Rad Laboratories, Inc. is a global leader in the development and manufacture of life science research and clinical diagnostics products. Founded in 1952 and headquartered in Hercules, California, the company operates internationally across the United States, Europe, Asia, Canada, and Latin America. Bio-Rad's core products span life science research instruments and consumables, including chromatography resins and media, flow cytometry antibodies, Droplet Digital PCR (ddPCR) platforms and reagents, as well as advanced digital PCR solutions designed for genomic research and applied sciences. In clinical diagnostics, Bio-Rad offers systems and assays for autoimmune testing, infectious disease detection, diabetes monitoring, blood typing and screening, cardiac assessment controls, molecular quality controls, veterinary diagnostics, and water quality testing. The company serves a broad range of customers from research institutions to clinical, hospital, and veterinary laboratories. Recent major changes include the acquisition of Stilla Technologies in the second quarter of 2025, which enhances Bio-Rad's digital PCR portfolio by integrating Stilla’s QX700 series instruments with Bio-Rad's existing QX Continuum system, thereby accelerating innovation in molecular diagnostics and precision medicine. In 2024, Bio-Rad also completed the acquisition of Saber Bio, a company focused on droplet technology for antibody discovery, aligning with its expansion in cell biology products. Additionally, Bio-Rad has launched new products such as the StarBright dyes for flow cytometry to improve multiplexing capabilities and kits for precise mutation detection in oncology applications leveraging its ddPCR technology. These developments support the company’s strategic focus on enhancing automation, throughput, and the sensitivity of its diagnostics platforms, further positioning it as a key player in advancing life science research and clinical diagnostic solutions. Bio-Rad continues to invest in transformative technologies such as Droplet Digital PCR for non-invasive cancer screening and gene therapy production, supported by ongoing product development and expansion of its assay portfolio. The company’s broad product offering includes instruments, software, reagents, and specialized consumables designed to support applications in cell biology, gene expression, protein purification, drug discovery, infectious diseases, and transfusion medicine. With a commitment to innovation and global healthcare advancement, Bio-Rad maintains a strong presence in both the life sciences and clinical diagnostics markets, driving growth through strategic acquisitions, product launches, and enhanced service offerings.
BIO-key Regains Compliance with Nasdaq Listing Rules; Nasdaq Trading Resumes on Wednesday, July 8th
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
BIO-key Showcases Passwordless & Biometric Identity Solutions at Jordan Banking Cybersecurity Workshop in Amman on July 6th
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 6.5% Rally? GF Value Says Undervalued
HKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026 Showcasing Life and Health Tech Strength
BIO CEO says more consistency needed in FDA review process
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
CJ BIO to Showcase TasteNrich® Taste Lab for Sodium Reduction, Clean Label, and Taste Design Solutions at IFT FIRST 2026
Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026
New Mexico Bioscience Delegation Showcases Innovation and Industry Growth at BIO International Convention 2026
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
Fujifilm Life Sciences at BIO 2026
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
BIO-key's Fireside Chat at Maxim Group Defense Tech Conf. to Webcast Thur.
BioHarvest Sciences to Present at the 2026 BIO International Convention
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Silexion Therapeutics to Attend BIO International Convention 2026
Enveric Biosciences Announces Participation in 2026 BIO International Convention